Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAOIB for Cognitive and Behavioral Symptoms in Dementia
NCT02103673Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Feb 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daoib in Alzheimer's disease (AD) and vascular dementia, sponsored by Chang Gung Memorial Hospital. Primary endpoints: Behavioral Pathology in Alzheimer's Disease Rating Scale at 6 weeks and Alzheimer's Disease Assessment Scale - cognitive subscale at 6 weeks. Started Feb 2014; status: completed.
02
Drugs
daoib
03
Conditions
Alzheimer's disease (AD)vascular dementia
Beyond the preview
Go deeper on NCT02103673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103673.